Endobiomedas - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 700 | 1,260 | 1,584 | 1,767 | 5,306 | 3,222 | 2,173 | 2,994 |
| Profit before tax | - | - | - | - | - | 701 | 594 | 144 |
| Net profit | -313 | 25 | -51 | -599 | 2,487 | 666 | 564 | 135 |
| Equity | -381 | -356 | -407 | -1,006 | 1,481 | 2,147 | 2,711 | 2,846 |
| Liabilities | 381 | 669 | 763 | 1,111 | 1,279 | 140 | 705 | 609 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 0 | 313 | 356 | 105 | 2,760 | 2,287 | 3,416 | 3,455 |
| Total assets | 0 | 313 | 356 | 105 | 2,760 | 2,287 | 3,416 | 3,455 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | - | 35 | 30 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +80.0% | +25.7% | +11.6% | +200.3% | -39.3% | -32.6% | +37.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | 8.0% | -14.3% | -570.5% | 90.1% | 29.1% | 16.5% | 3.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | 167.9% | 31.0% | 20.8% | 4.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -44.7% | 2.0% | -3.2% | -33.9% | 46.9% | 20.7% | 26.0% | 4.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | 21.8% | 27.3% | 4.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 0.9 | 0.1 | 0.3 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Endobiomedas - Social security debts
The company had no debts to Sodra
Endobiomedas - VMI tax arrears
As of 2026-09-14, the amount of overdue STI tax debt of the company Endobiomedas is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-06-18 | 2026-09-14 | 0.09 |
| 2025-07-01 | 2026-06-01 | 0.09 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Endobiomedas, MB (code 304738306) is a Lithuanian small partnership engaged in general medical practice activities. In 2025, the company generated revenue of €3.0K, up from €2.2K in 2024 after €3.2K in 2023, showing a volatile but modest revenue pattern over the three-year period. Net profit in 2025 was €135, compared with €564 in 2024 and €666 in 2023, which indicates that profitability weakened despite the revenue rebound. The 2025 net profit margin was 4.5%, well below the 26.0% achieved in 2024. At year-end 2025, total assets amounted to €3.5K, equity to €2.8K and liabilities to €609, leaving the balance sheet strongly equity-backed. Key ratios for 2025 support this picture: return on equity was 4.7%, return on assets 3.9%, debt-to-equity 0.21, equity ratio 82.4% and asset turnover 0.87x. No staff data was provided, so revenue per employee cannot be assessed.